member
filovirida
famili
includ
marburg
viru
marv
sever
speci
ebola
viru
envelop
filamentshap
virus
nonseg
negativesens
rna
genom
infect
human
caus
sever
haemorrhag
fever
case
occur
resourcepoor
set
subsaharan
africa
case
fatal
rate
rang
monocyt
macrophag
dendrit
cell
thought
site
viral
replic
earli
later
stage
yet
viral
amplif
also
occur
endotheli
cell
mani
consist
rapid
spread
broad
rang
cell
type
tissu
human
filovirus
found
readili
enter
broad
rang
cultur
cell
type
notabl
except
emerg
recent
year
filovir
rout
cell
entri
interact
target
cell
incom
virion
mediat
viral
side
heterotrim
filovir
glycoprotein
gp
subunit
gener
furinmedi
cleavag
singl
precursor
gp
remain
link
disulfid
numer
factor
surfac
host
cell
report
interact
includ
folat
member
famili
receptor
tyrosin
kinas
axl
dtk
mer
cell
immunoglobulin
mucin
domain
although
relev
folat
receptor
filoviru
entri
later
addit
numer
ctype
lectin
calciumdepend
carbohydratebind
molecul
includ
asialoglycoprotein
dcsign
human
macrophag
galactosetyp
ctype
liver
lymph
node
sinusoid
endotheli
cell
ctype
report
interact
promot
filoviru
entri
follow
host
cell
bind
filovirus
taken
cell
like
low
phdepend
cathepsin
blmediat
cleavag
filoviru
gp
requir
fusion
late
endosom
addit
endosom
cholesterol
transport
act
essenti
intracellular
intric
multistep
rout
viral
entri
like
requir
form
coordin
may
take
advantag
cellular
signal
shown
coxsacki
group
b
hepat
c
inde
kinaseakt
pathway
well
protein
kinas
c
small
cellular
gtpase
implic
filoviru
although
discuss
sever
experiment
antifilovir
approach
report
vaccin
specif
antivir
treatment
yet
establish
given
low
case
number
geograph
restrict
resourcelimit
region
industrysustain
drug
develop
programm
unlik
nonetheless
clear
unmet
clinic
need
natur
occur
case
well
addit
potenti
need
given
filovirus
consid
cdc
categori
bioterror
agent
wwwbtcdcgovbioterror
given
complex
filovir
rout
entri
hypothes
drug
perturb
cellular
signal
network
approv
indic
might
also
interfer
filoviru
entri
perform
smallscal
screen
found
amiodaron
multiion
channel
inhibitor
use
clinic
antiarrhythm
agent
act
potent
specif
inhibitor
filovir
cell
entri
concentr
amiodaron
requir
filoviru
inhibit
well
within
rang
achiev
serum
antiarrhythm
therapi
human
ie
pharmacolog
agent
purchas
sanofiaventi
frankfurt
germani
amiodaron
sigmaaldrich
taufkirchen
germani
amiodaron
dronedaron
egcg
ethosuximid
lidocain
metoprolol
merck
millipor
darmstadt
germani
zphetyr
tbu
diazomethylketon
fydmk
toronto
research
chemic
toronto
canada
artesun
cyclosporin
erlotinib
fingolimod
imatinib
rapamycin
sorafenib
sotrastaurin
sunitinib
abbott
wiesbaden
germani
verapamil
roch
pharma
grenzachwyhlen
germani
bevacizumab
janssencilag
neuss
germani
haloperidol
astella
pharma
munich
germani
theophyllin
immort
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
fetal
calf
serum
fc
nonessenti
amino
acid
lglutamin
penicillinstreptomycin
primari
human
umbil
vein
endotheli
cell
isol
umbil
cord
previous
cultiv
medium
lonza
basel
switzerland
contain
fc
penicillinstreptomycin
primari
human
hepatocyt
isol
use
modifi
twostep
collagenas
roch
p
mannheim
germani
perfus
techniqu
previous
cultur
william
medium
e
biochrom
ag
berlin
germani
supplement
insulin
dexamethason
penicillinstreptomycin
sodium
pyruv
hepe
buffer
lglutamin
fc
gener
macrophag
primari
human
monocyt
recent
briefli
ficol
gradientpurifi
human
monocyt
peripher
blood
mononuclear
cell
cultur
rpmi
medium
human
fibrindeplet
plasma
penicillinstreptomycin
h
cell
resuspend
xvivo
medium
supplement
human
fibrindeplet
plasma
penicillinstreptomycin
seed
allow
differenti
least
day
medium
chang
everi
day
plasmid
encod
firefli
luciferas
context
gut
lentivir
genom
hiv
gagpol
vesicular
stomat
viru
vsv
gprotein
vsvg
basi
product
lentivir
pseudoparticl
previous
plasmid
plasmid
z
r
ic
encod
gp
zair
ebola
viru
ebov
well
reston
sudan
ivori
coast
tai
forrest
ebola
viru
respect
kind
gift
dr
gari
nabel
anthoni
sanchez
nih
bethesda
usa
plasmid
pcmvlassagpc
encod
gp
lassa
viru
kind
gift
dr
francoislo
cosset
inserm
lyon
franc
plasmid
pwrghtnm
x
encod
gp
hantaan
viru
kind
gift
dr
jay
hooper
usamriid
fort
detrick
usa
plasmid
encod
gp
new
world
arenaviru
guanarito
kind
gift
dr
hyeryun
choe
harvard
medic
school
boston
usa
stefan
kunz
univers
lausann
switzerland
pseudoparticl
gener
cotransfect
plasmid
encod
gut
lentivir
genom
contain
firefli
luciferas
gene
ii
hiv
gagpol
iii
desir
envelop
gp
day
transfect
cell
seed
mm
well
next
day
total
dna
transfect
per
well
use
polyethylenimin
medium
replac
h
supernat
harvest
h
h
transfect
pool
filter
pore
size
use
immedi
store
week
week
pseudoparticl
transduct
assay
perform
format
use
eahi
cell
per
well
seed
number
adjust
cell
line
transduct
carri
polybren
without
drug
h
medium
exchang
h
cell
lyse
luciferas
measur
previous
separ
viru
drug
use
amicon
centrifug
devic
kda
cutoff
millipor
devic
pretreat
pseudoviru
wash
ml
drugfre
media
three
time
centrifug
rpm
work
infecti
mayinga
strain
ebov
genbank
access
number
perform
highest
safeti
precaut
biosafeti
level
facil
institut
virolog
philippsunivers
marburg
germani
vero
cell
infect
ebov
multipl
infect
moi
ebov
particl
purifi
supernat
infect
cell
h
postinfect
centrifug
sucros
cushion
min
rpm
beckman
ultracentrifug
use
rotor
beckman
coulter
palo
alto
ca
usa
pellet
resuspend
pb
amiodaron
mix
concentr
ebov
particl
moi
transfer
eahi
cell
h
incub
inoculum
remov
replac
fresh
dmem
supplement
fc
h
postinfect
cell
fix
paraformaldehyd
h
remov
laboratori
subject
quantit
immunofluoresc
analysi
immunostain
infect
cell
perform
describ
immunofluoresc
analys
carri
previous
detect
nucleocapsid
np
induc
inclus
bodi
ebovinfect
eahi
cell
fixat
cell
paraformaldehyd
dmem
h
use
monoclon
antiebov
np
antibodi
secondari
fitccoupl
goat
antimous
antibodi
numer
comparison
group
made
unpair
twosid
student
ttest
differ
p
valu
refer
signific
p
p
indic
singl
doubl
asterisk
throughout
graphpad
prism
softwar
la
jolla
ca
usa
use
fit
curv
determin
inhibitori
concentr
base
literatur
review
select
drug
initi
screen
drug
chosen
met
sever
follow
select
criteria
known
safeti
profil
human
ii
known
perturb
cell
signal
process
iii
recogn
antivir
properti
virus
member
filovirida
iv
coverag
broad
rang
indic
drug
class
drug
approv
ema
fda
variou
indic
one
drug
protein
kinas
c
inhibitor
sotrastaurin
advanc
clinic
develop
immunosuppress
agent
use
organ
transplant
recipi
human
endotheliumderiv
eahi
cell
transduc
pseudoparticl
bear
either
ebov
gp
marv
gp
presenc
absenc
drug
drug
concentr
test
base
serum
level
achiev
human
four
concentr
test
per
drug
two
round
screen
perform
cathepsin
b
l
inhibitor
fydmk
known
potent
inhibit
ebov
gpmediat
cell
entri
includ
posit
control
figur
drug
major
effect
filoviru
gpmediat
cell
entri
amiodaron
found
reduc
detect
signal
thu
strongli
fydmk
achiev
inhibit
amiodaronemedi
inhibit
ebov
marv
gpbear
pseudoparticl
show
respect
figur
expos
eahi
cell
stabli
express
firefli
luciferas
differ
concentr
amiodaron
test
cytotox
antiprolif
effect
signal
reduct
seen
figur
correspond
calcul
therapeut
index
ebov
marv
respect
worst
case
scenario
assum
true
sd
sd
determin
index
still
ebov
marv
assess
effect
amiodaron
authent
filoviru
entri
eahi
cell
expos
purifi
ebov
presenc
differ
concentr
amiodaron
h
medium
exchang
h
later
cell
fix
paraformaldehyd
stain
ebov
np
protein
dapi
use
counterstain
clear
concentrationdepend
reduct
percentag
npposit
cell
overal
cell
number
unchang
supplementari
data
signific
inhibit
observ
amiodaron
concentr
higher
figur
averag
experi
perform
correspond
calcul
therapeut
index
note
appar
flatter
slope
concentr
respons
curv
like
due
fact
experi
perform
separ
occas
averag
thu
authent
filovirus
may
sensit
amiodaron
inhibit
pseudoparticl
bear
filovir
gp
next
aim
assess
whether
amiodaron
inhibit
entri
driven
gp
filoviru
speci
whether
entri
mediat
gp
viral
famili
may
affect
pseudoparticl
bear
gp
ebola
viru
speci
tai
forest
reston
sudan
zair
well
marv
similarli
inhibit
amiodaron
figur
thu
amiodaron
blocker
cell
entri
mediat
viral
gp
across
filovirida
famili
among
broader
rang
human
pathogen
envelop
virus
enter
target
cell
endocytosi
phdepend
manner
observ
signific
inhibit
pseudovirus
bear
gp
new
world
arenaviru
guanarito
figur
vsvg
rhabdovirida
famili
lassa
viru
gp
old
world
arenaviru
hantaan
bunyavirida
famili
viru
gppseudotyp
lentivirus
affect
lesser
extent
sinc
pseudovirus
lentivir
np
report
genom
differ
strongli
support
fact
amiodaron
exert
inhibitori
effect
viral
cell
entri
ie
replic
cycl
step
point
fusion
viral
envelop
cellular
membran
next
test
effect
target
cell
pretreat
amiodaron
present
either
h
cell
wash
three
time
ebov
marv
pseudoparticl
ad
cell
h
cell
expos
pseudoparticl
figur
observ
mark
inhibit
drug
present
throughout
experi
ie
h
prior
addit
pseudovirus
h
follow
setup
amiodaron
present
cell
entri
phase
case
marv
also
signific
inhibit
drug
present
pseudoparticl
ad
cell
suggest
celldirect
mechan
action
howev
effect
target
cell
appear
revers
upon
remov
drug
moreov
ebov
pseudoviru
incub
high
concentr
amiodaron
wash
kda
filter
devic
order
remov
drug
observ
subsignific
reduct
infect
rel
vsvg
pseudovirus
supplementari
data
next
assess
whether
eahi
cell
could
adapt
amiodaron
grow
presenc
amiodaron
week
prior
experiment
cell
growth
larg
unalt
obviou
morpholog
alter
observ
compar
degre
inhibit
ebov
marv
pseudoparticl
suggest
prolong
exposur
amiodaron
lead
compensatori
chang
host
cell
figur
next
evalu
amiodaron
inhibit
cell
entri
mediat
filovir
gp
rang
differ
target
cell
signific
inhibit
cell
line
test
although
appear
trend
toward
pronounc
effect
cell
line
endotheli
origin
compar
epitheli
cell
line
cell
line
fibroblast
origin
appear
least
sensit
figur
filovir
gpmediat
entri
primari
human
umbil
vein
endotheli
cell
macrophag
deriv
primari
human
monocyt
significantli
inhibit
amiodaron
concentr
marv
ebov
gp
amiodaron
effect
transduct
primari
hepatocyt
supplementari
data
cell
typespecif
differ
also
keep
host
celltarget
mechan
action
amiodaron
amiodaron
inhibit
otherwis
modul
number
cellular
target
includ
potassium
channel
sodium
channel
calcium
channel
use
specif
pharmacolog
agent
test
whether
observ
antifilovir
effect
associ
known
pharmacodynam
properti
amiodaron
dronedaron
newer
drug
pharmacodynam
profil
similar
amiodaron
show
mark
concentrationdepend
inhibit
marv
ebov
gpbear
pseudoparticl
similar
amiodaron
figur
ltype
calcium
channel
blocker
verapamil
similarli
inhibit
filoviru
gpmediat
entri
although
higher
absolut
molar
concentr
requir
figur
convers
select
ttype
calcium
channel
blocker
ethosuximid
effect
sodium
channel
blocker
lidocain
adrenoreceptor
antagonist
metoprolol
nonselect
potassium
channel
blocker
sotalol
also
without
detect
effect
figur
drug
concentr
chosen
base
plasma
level
report
achiev
human
relev
toxic
antiprolif
effect
concentr
use
exclud
use
eahi
cell
line
stabli
express
luciferas
report
supplementari
data
thu
sever
agent
either
nonspecif
ion
channel
inhibitor
amiodaron
dronedaron
inhibitor
ltype
calcium
channel
verapamil
inhibit
cell
entri
mediat
filovir
gp
agent
possess
multipl
pharmacodynam
effect
amiodaron
paper
describ
identif
amiodaron
drug
act
inhibitor
ion
channel
dronedaron
verapamil
inhibitor
filoviru
cell
entri
show
amiodaron
concentr
routin
reach
human
serum
amiodaron
employ
clinic
act
host
celltarget
agent
block
viral
entri
absenc
approv
treatment
manag
filovir
haemorrhag
fever
larg
limit
support
care
contain
mortal
high
resourcepoor
set
even
modern
intens
care
avail
treatment
sever
potenti
approach
suggest
base
vitro
anim
data
includ
monoclon
antibodi
isol
lipidstabil
smallinterf
rna
direct
viral
recombin
vsvbase
howev
difficult
transfer
highli
experiment
approach
routin
clinic
care
recent
oestrogen
receptor
modul
clomiphen
licens
ovarian
stimul
human
report
inhibit
filoviru
infect
possibl
perturb
role
filovir
amiodaron
avail
oral
intraven
formul
use
decad
longterm
shortterm
treatment
cardiac
arrhythmia
gener
drug
use
would
feasibl
resourcerich
resourcepoor
set
known
narrow
therapeut
window
serum
level
treat
cardiac
arrhythmia
rang
vitro
observ
authent
known
side
effect
amiodaron
includ
ocular
pulmonari
toxic
thyroid
dysfunct
proarrhythm
effect
gener
manag
especi
short
term
importantli
would
clearli
accept
drug
time
increas
odd
surviv
set
acut
filovir
haemorrhag
fever
given
filovir
haemorrhag
fever
involv
spread
infect
broad
rang
cell
tissu
plausibl
potent
entri
inhibitor
would
limit
system
spread
henc
might
reduc
mortal
howev
clinic
studi
would
need
determin
point
know
exact
mechan
amiodaron
antiarrhythm
agent
studi
inhibit
filovir
cell
entri
sever
observ
suggest
amiodaron
act
host
cell
rather
incom
virion
preincub
target
cell
drug
also
inhibitori
effect
marv
ii
pronounc
effect
seen
drug
present
infect
iii
inhibitori
effect
cell
type
depend
sens
detect
variabl
extent
cell
type
test
notabl
except
primari
human
hepatocyt
howev
also
trend
reduc
infect
pseudovirus
pretreat
amiodaron
wash
ad
target
cell
might
suggest
either
unabl
complet
separ
drug
viru
amiodaron
inhibit
requir
form
ternari
interact
drug
filoviru
host
cell
least
two
hypothes
amiodaron
may
render
host
cell
less
suscept
filovir
entri
one
hand
amiodaron
dronedaron
report
perturb
late
step
endosom
process
result
lipid
accumul
gross
alter
endosom
structur
phenotyp
thought
reminisc
type
c
besid
filovirus
new
world
arenaviru
guanarito
also
strongli
inhibit
amiodaron
virus
test
sinc
thought
enter
target
cell
via
late
endosom
would
consist
amiodaronemedi
perturb
inde
shoemak
et
al
report
clomiphen
relat
inhibitor
filovir
entri
identifi
common
cation
amphiphil
caus
accumul
cholesterol
could
due
inhibit
acid
sphingomyelinas
broad
rang
cation
amiodaron
dronedaron
verapamil
pka
valu
fit
categori
moreov
entri
late
endosom
also
suggest
hantavirus
one
modestli
inhibit
amiodaron
differ
studi
inhibitori
effect
high
concentr
amiodaron
sever
acut
respiratori
syndrom
coronaviru
paper
suggest
inhibit
infect
occur
fusion
viral
envelop
late
endosom
membran
deliveri
viral
genom
cytosol
sinc
block
postfus
step
would
expect
affect
pseudovirus
equal
explain
observ
pseudovirus
inhibit
amiodaron
other
second
hypothesi
inhibit
filovir
entri
antiarrhythm
agent
link
primari
pharmacodynam
properti
amiodaron
pleiotrop
drug
known
target
potassium
channel
sodium
channel
calcium
channel
receptor
test
agent
narrow
rang
molecular
target
ltype
calcium
channel
blocker
verapamil
exhibit
antifilovir
effect
find
may
suggest
role
calcium
current
filovir
entri
role
obviou
excit
tissu
muscl
neuron
cell
ltype
calcium
channel
also
present
mani
nonexcit
cell
includ
endotheli
epitheli
calcium
flux
caus
rapid
shift
intracellular
calcium
level
import
part
cellular
signal
process
notabl
mayb
phospholipas
trisphosphatediacylglycerol
thu
interfer
calciummedi
cell
signal
event
requir
orchestr
filovir
entri
anoth
plausibl
mechan
interestingli
recent
report
gabapentin
verapamil
inhibitor
voltageg
calcium
channel
well
sirnamedi
knockdown
calcium
channel
subunit
inhibit
infect
new
world
arenaviru
ongo
work
aim
test
hypothes
determin
exact
mechan
filoviru
inhibit
amiodaron
antiarrhythm
agent
work
present
show
limitedscal
screen
drug
known
safeti
profil
human
reveal
novel
antivir
properti
may
use
address
rare
yet
sever
infect
drug
discoveri
programm
like
initi
chanc
identifi
potenti
use
agent
may
best
virus
employ
complex
cell
entri
rout
filovirus
discoveri
unexpect
antivir
properti
known
drug
cellular
target
may
time
offer
novel
insight
molecular
mechan
interact
new
therapeut
approach
work
support
emmi
noether
fellowship
deutsch
forschungsgemeinschaft
v
h
author
declar
conflict
interest
relev
work
